Rhythm Pharmaceuticals Stock Today
| RYTM Stock | USD 52.04 2.19 4.04% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Rhythm Pharmaceuticals is selling at 52.04 as of the 22nd of March 2025; that is 4.04 percent decrease since the beginning of the trading day. The stock's lowest day price was 51.87. Rhythm Pharmaceuticals has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of October 2017 | Category Healthcare | Classification Health Care |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. The company has 63.22 M outstanding shares of which 5.41 M shares are at this time shorted by private and institutional investors with about 10.99 trading days to cover. More on Rhythm Pharmaceuticals
Moving together with Rhythm Stock
Moving against Rhythm Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Rhythm Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Chairman | David MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRhythm Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rhythm Pharmaceuticals' financial leverage. It provides some insight into what part of Rhythm Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rhythm Pharmaceuticals (RYTM) is traded on NASDAQ Exchange in USA. It is located in 222 Berkeley Street, Boston, MA, United States, 02116 and employs 283 people. Rhythm Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.43 B. Rhythm Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.22 M outstanding shares of which 5.41 M shares are at this time shorted by private and institutional investors with about 10.99 trading days to cover.
Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64.
Check Rhythm Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Rhythm Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rhythm Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rhythm Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rhythm Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Rhythm Ownership Details
Rhythm Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Driehaus Capital Management Llc | 2024-12-31 | 1.3 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.3 M | |
| Hhg Plc | 2024-12-31 | 1.2 M | |
| Alkeon Capital Management, Llc | 2024-12-31 | 1.2 M | |
| Rock Springs Capital Management Lp | 2024-12-31 | 1.2 M | |
| Checkpoint Capital Lp | 2024-12-31 | 728 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 692.8 K | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 685.2 K | |
| Hood River Capital Management Llc | 2024-12-31 | 643.7 K | |
| Blackrock Inc | 2024-12-31 | 7 M | |
| Primecap Management Company | 2024-12-31 | 6.6 M |
Rhythm Pharmaceuticals Historical Income Statement
Rhythm Stock Against Markets
Rhythm Pharmaceuticals Corporate Management
| Jennifer Lee | Executive America | Profile | |
| Yann Mazabraud | Executive International | Profile | |
| Christopher German | Principal Controller | Profile | |
| Sarah Ryan | Vice Marketing | Profile | |
| Jim Flaherty | Senior Counsel | Profile | |
| David Connolly | Head Communications | Profile | |
| Joseph Shulman | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.34) | Revenue Per Share | Quarterly Revenue Growth 0.726 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.